Phase I Open Label Trial to Assess Safety of BIBW 2992 in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 04 Nov 2014
At a glance
- Drugs Afatinib (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 25 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Oct 2013 Planned end date changed from 1 May 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 25 Jul 2012 Planned End Date changed from 1 Sep 2012 to 1 May 2013 as reported by ClinicalTrials.gov.